Literature DB >> 4615787

Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).

P J Creaven, S J Newman, O S Selawry, M H Cohen, A Primack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4615787

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN： 0069-0112


× No keyword cloud information.
  10 in total

1.  Phase II study of VP 16-213 (etoposide) in metastatic transitional cell urothelial cancer.

Authors:  B A Ponder; R T Oliver
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

Review 2.  VP16-213 (etoposide). A critical review of its activity.

Authors:  F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 3.  The clinical pharmacology of VM26 and VP16-213. A brief overview.

Authors:  P J Creaven
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 4.  Antineoplastic drugs: clinical pharmacology and therapeutic use.

Authors:  R A Bender; L A Zwelling; J H Doroshow; G Y Locker; K R Hande; D S Murinson; M Cohen; C E Myers; B A Chabner
Journal:  Drugs       Date:  1978-07       Impact factor: 9.546

Review 5.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 6.  Current development of podophyllotoxins.

Authors:  R Canetta; P Hilgard; S Florentine; P Bedogni; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung.

Authors:  H Roed; L L Vindelov; I J Christensen; M Spang-Thomsen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies.

Authors:  B L Powell; H B Muss; R L Capizzi; M E Caponera; D R White; P J Zekan; J N Atkins; D V Jackson; F Richards; J B Craig
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 9.  Podophyllotoxin derivative VP 16-213.

Authors:  A M Arnold
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

10.  [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].

Authors:  H J Schmoll; N Niederle; W Achterrath
Journal:  Klin Wochenschr       Date:  1981-11-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.